

Technical Review Panel Member

Curriculum Vitae

Name: Dr. Vivian Cox
 Nationality: American citizen, South African permanent resident
 Additional languages: Basic French
 Expertise: TB Expert

Qualifications

Qualification	Institution	Department	Year
Honorary Research Associate	School of Public Health and Medicine, Faculty of Health Sciences, University of Cape Town, South Africa	Centre for Infectious Disease Epidemiology and Research (CIDER)	2016
Infectious Diseases Fellowship	University of Colorado Health Science Center, Denver, Colorado, USA	School of Medicine, Division of Infectious Diseases	2009
Internal Medicine Residency	University of Colorado Health Science Center, Denver, Colorado, USA	School of Medicine, Division of Internal Medicine	2007
Doctor of Medicine	University of Colorado Health Science Center, Denver, Colorado, USA	School of Medicine	2003
Bachelor of Arts, Human Biology	Stanford University, Palo Alto, California, USA and Stanford Overseas Program, Oxford University, Oxford, England	Undergraduate Program in Human Biology	1991

Employment History

Employer	Position	Place	Year
Desmond Tutu TB Centre, Department of Paediatrics	Lead Physician, Output 1, BENEFIT Kids Project	Stellenbosch University, Cape Town, South Africa	2019 – current
<i>Médecins Sans Frontières, France</i>	Sub-Principal Investigator, endTB Clinical Trial	endTB trial site, Khayelitsha, Cape Town, South Africa	2019 – present
USAID/Stop TB Partnership	Multi-Drug Resistant TB Clinical Consultant	Multi-country	2017 – present

<i>Médecins Sans Frontières, Belgium</i>	Medical Project Manager, Khayelitsha TB/HIV Project	Khayelitsha, Cape Town, South Africa	2011 – 2016
University of California, San Diego	Assistant Professor, Department of Medicine	University of California, San Diego, California, USA	2009 – 2011

Relevant Publications

1. **V Cox**, L McKenna, R Acquah, A Reuter, et al. *Clinical Perspectives on Treatment of Rifampicin-Resistant/Multidrug-Resistant Tuberculosis*. International Journal of Tuberculosis and Lung Disease, accepted June 2020, publication pending.
2. I Zabsonre, SS Thi, **V Cox**. *Improving access to newer drugs for multi-drug resistant tuberculosis treatment with targeted short-term technical assistance to strengthen clinical and programmatic capacity*. International Journal of Tuberculosis and Lung Disease, accepted May 2020, publication pending.
3. **V Cox**, L Wilkinson, A Grimsrud, J Hughes, A Reuter, F Conradie, J Nel, T Boyles. *Critical changes to services for TB patients during the COVID-19 pandemic*. International Journal of Tuberculosis and Lung Disease, April 2020.
4. J Sharp, L Wilkinson, **V Cox**, C Cragg, G van Cutsem, A Grimsrud. *Outcomes of patients enrolled in an Antiretroviral Adherence Club after viral re-suppression*. Southern African Journal of HIV Medicine. May 2019.
5. **V Cox**, H Cox, M Pai, J Stillo, B Citro, G Brigden. *Health care gaps in the global burden of drug resistant tuberculosis*. International Journal of Tuberculosis and Lung Disease State of the Art Series, February 2019.
6. I Monedero-Recuero, L Hernando-Marrupe, A Sanchez-Montalva, **V Cox**, M Tommasi, J Furin, C-Y Chiang, M Quelapio, KG Koura, A Trebucq, X Padanilam, G Dravniece, A Piubello. *QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment*. International Journal of Tuberculosis and Lung Disease, September 2018.
7. **V Cox**, G Brigden, RH Crespo, E Lessem, S Lynch, ML Rich, B Waning, J Furin. *Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis*. International Journal of Tuberculosis and Lung Disease, April 2018.
8. **V Cox**, J Furin. *WHO recommendations for multidrug-resistant tuberculosis: should different standards be applied?* International Journal of Tuberculosis and Lung Disease, November 2017.
9. A Reuter, P Tisile, D von Delft, H Cox, **V Cox**, L Ditiu, A Garcia-Prats, S Koenig, E Lessem, R Nathavitharana, J Seddon, J Stillo, A von Delft, J Furin. *The devil we know: is use of injectable agents for treatment of multidrug-resistant tuberculosis justified?* International Journal of Tuberculosis and Lung Disease, November 2017.
10. E Lessem, **V Cox**, J Furin. *Bedaquiline or delamanid in the treatment of rifampin-resistant tuberculosis*. Lancet Respiratory Medicine, September 2017.
11. J Furin, E Lessem, **V Cox**. *Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis*. European Respiratory Journal, August 2017.
12. E Mohr, J Daniels, B Beko, P Isaakidis, **V Cox**; SJ Steele, O Muller, L Snyman, V De Azevedo, A Shroufi, L Trivino Duran, J Hughes. *DOT or SAT for Rifampicin-*

- Resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.* PLoS ONE, June 2017.
13. R Cariem, **V Cox**, V Azevedo, J Hughes, E Mohr, L Trivino Duran, N Ndjeka, J Furin. *The Experience of Bedaquiline Implementation at a Decentralized Clinic in South Africa.* Public Health Action, July 2016.
 14. J Sharp, L Wilkinson, **V Cox**, C Cragg, G van Cutsem, A Grimsrud. *Outcomes of Patients Enrolled in Antiretroviral Therapy Adherence Clubs after Viral Re-Suppression.* JIAS, July 2016.
 15. G Perez, **V Cox**, T Ellman, A Moore, G Patten, A Shroufi, K Stinson, G van Cutsem, M Ibetu. *'I know that I do have HIV but nobody saw me': oral HIV self-testing in an informal settlement in South Africa.* PLoS ONE, April 2016.
 16. M Schomaker, MA Davies, K Malateste, L Renner, S Sawry, S N'Gbeche, K Technau, F Eboua, F Tanser, H Sygnate-Sy, S Phiri, M Amorissani-Folquet, **V Cox**, F Koueta, C Chimbete, A Lawson-Evi, J Giddy, C Amani-Bosse, R Wood, M Egger, V Leroy, on behalf of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) West Africa and IeDEA Southern Africa collaboration. *Growth and mortality outcomes for different antiretroviral therapy initiation criteria in children ages 1-5 years.* Epidemiology, March 2016.
 17. M Schomaker, M Egger, J Ndirangu, S Phiri, H Moultrie, K Technau, **V Cox**, J Giddy, C Chimbete, R Wood, T Gsponer, C Moore, H Rabie, B Eley, L Muhe, M Penazzato, S Essajee, O Keiser, MA Davies, for the International Epidemiologic Databases to Evaluate AIDS–Southern Africa (IeDEA-SA) Collaboration. *Optimal timing of antiretroviral treatment initiation in HIV positive children and adolescents – a multiregional analysis from Southern Africa, West Africa, and Europe.* International Journal of Epidemiology, January 2016.
 18. E Mohr, J Hughes, L Snyman, B Beko, X Harmans, J Caldwell, H Duvivier, L Wilkinson, **V Cox**. *Patient support interventions to improve adherence to drug-resistant tuberculosis treatment: A counselling toolkit.* South African Medical Journal, August 2015.
 19. J Bernheimer, G Patten, T Makeleni, N Mantangana, N Dumile, E Goemare, **V Cox**. *Paediatric HIV Treatment Failure: A Silent Epidemic.* JIAS, June 2015.
 20. H Cox, J Furin, C Mitnick, C Daniels, **V Cox**, E Goemaere. *The need to accelerate access to new drugs for multi-drug resistant tuberculosis.* Bulletin of the World Health Organization, May 2015.
 21. E Mohr, **V Cox**, L Wilkinson, S Moyo, J Hughes, J Daniels, O Muller, H Cox. *Programmatic treatment outcomes in HIV infected and uninfected drug-resistant tuberculosis patients in Khayelitsha, South Africa.* Transactions of the Royal Society of Tropical Medicine and Hygiene, May 2015.
 22. A Nelson, J Maritz, J Giddy, L Frigati, H Rabie, G van Cutsem, T Mutseyekwa, N Jange, J Bernheimer, M Cotton, **V Cox**. *HIV testing and antiretroviral therapy initiation at birth: views from a primary care setting in Khayelitsha.* Southern African Journal of HIV Medicine, April 2015.
 23. S Moyo, H Cox, J Hughes, J Daniels, L Synman, V De Azevedo, A Shroufi, **V Cox**, G van Cutsem. *Loss from Treatment for Drug Resistant Tuberculosis: Risk Factors and Patient Outcomes in a Community-Based Program in Khayelitsha, South Africa.* PLoS One, March 2015.

24. J Hughes, P Isaakidis, A Andries, H Mansoor, **V Cox**, G Meintjes, H Cox. *Linezolid for multidrug-resistant tuberculosis in HIV-infected and-uninfected patients*. European Respiratory Journal, February 2015.
25. H Cox, J Daniels, O Muller, M Nicol, **V Cox**, G van Cutsem, J Hughes. *Impact of decentralized care and the Xpert MTB/RIF test on rifampicin-resistant tuberculosis treatment initiation in Khayelitsha, South Africa*. Open Forum Infectious Diseases, January 2015.
26. N Ford, K Stinson, MA Davies, V Cox, G Patten, C Cragg, G van Cutsem, A Boulle. *Is it safe to drop CD4 monitoring among virologically suppressed patients? A cohort evaluation from Khayelitsha, South Africa*. AIDS, August 2014.
27. H Cox, G Van Cutsem, **V Cox**. *Better XDR-TB treatment needed in South Africa*. Lancet, July 2014.
28. L Salazar-Vizcaya, O Keiser, K Technau, MA Davies, A Haas, N Blaser, **V Cox**, B Eley, H Rabie, H Moultrie, J Giddy, R Wood, M Egger, J Estill. *Viral load versus CD4 monitoring and outcomes of ART in HIV-positive children in Southern Africa: a cohort-based modelling study*. AIDS, June 2014.
29. H Moultrie, R Wood, MA Davies, A Coovadia, A van der Schyff, E Muchiri,, H Rabie, **V Cox**, M Schomaker, L Salazar, L Kuhn, B Eley. *Virological response in children treated with abacavir- compared to stavudine-based antiretroviral treatment - a South African multi-cohort analysis* Paediatric Infectious Disease Journal, June 2014.
30. H Cox, J Furin, C Mitnick, C Daniels, **V Cox**, E Goemaere. *Accelerated access to new drugs for multidrug-resistant tuberculosis: innovations to complement clinical trials are urgently needed*. Lancet Infectious Diseases, March 2014.
31. K Stinson, **V Cox**, E Goemaere, N Ford. *Patients lost to care are more likely to be viraemic than patients still in care*. Clinical Infectious Diseases, March 2014.
32. M Ibeto, J Giddy, **V Cox**. *Closing the gaps – steps towards elimination of mother to child transmission of HIV*. Southern African Journal of HIV Medicine, March 2014.
33. K Stinson, J Giddy, **V Cox**, R Burton, M Ibeto, C Cragg, G van Cutsem, K Hilderbrand, A Boulle, D Coetzee, E Goemaere. *Reflections on a decade of delivering PMTCT in Khayelitsha, Cape Town*. Southern African Journal of HIV Medicine, March 2014.
34. H Cox, G van Cutsem, **V Cox**. *Correspondence: long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study*. Lancet, February 2014.
35. S Moyo, H Cox, J Hughes, J Daniels, L Snyman, V de Azevedo, S Abrahams, A Shroufi, **V Cox**, G van Cutsem. *Loss from treatment for drug resistant tuberculosis: Risk factors and patient outcomes in a community-based program in Khayelitsha, South Africa*. PLOS One, February 2014.
36. T Boyles, J Hughes, **V Cox**, R Burton, G Meintjes, M Mendelson. *False positive Xpert® MTB/RIF assays in previously treated patients: a cause for caution in interpreting results*. International Journal of Tuberculosis and Lung Disease, December 2013.
37. L Salazar-Vizcaya, O Keiser, K Technau, MA Davies, A Haas, N Blaser, **V Cox**, B Eley, H Rabie, H Moultrie, J Giddy, R Wood, M Egger, J Estill. *Monitoring*

and outcomes of antiretroviral therapy in HIV infected children in Southern Africa – a cohort-based modelling study. AIDS, December 2013.

38. M Schomaker, M Egger, J Ndirangu, S Phiri, H Moultrie, K Technau, **V Cox**, J Giddy, C Chimbetete, R Wood, T Gsponer, C Moore, H Rabie, B Eley, L Muhe, M Penazzato, S Essajee, O Keiser, M Davies, for the International Epidemiologic Databases to Evaluate AIDS–Southern Africa (IeDEA-SA) Collaboration. *When to Start Antiretroviral Therapy in Children Aged 2–5 Years: A Collaborative Causal Modelling Analysis of Cohort Studies from Southern Africa.* PLOS Medicine, November 2013.
39. K Conradie, L Wilkinson, **V Cox**. *Supporting adherence to antiretroviral treatment: a facility approach to reduce the risk of treatment failure.* HIV Clinician’s Society Nursing Matters, September 2013.
40. C Bateman, **V Cox**, J Giddy, R Burton. *Much ado over the new South African PMTCT guidelines.* South African Medical Journal, April 2013.
41. MA Davies, S Phiri, R Wood, M Wellington, **V Cox**, C Bolton-Moore, V Timmerman, H Moultrie, J Ndirangu, H Rabie, K Technau, J Giddy, N Maxwell, A Boulle, O Keiser, M Egger, B Eley. *Temporal trends in the characteristics of children at antiretroviral therapy initiation in Southern Africa: The IeDEA-SA Collaboration.* PLoS One, April 2013.